Campbell Newman Asset Management Inc. Acquires 166 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Campbell Newman Asset Management Inc. boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.4% in the first quarter, Holdings Channel reports. The firm owned 11,619 shares of the company’s stock after purchasing an additional 166 shares during the quarter. Campbell Newman Asset Management Inc.’s holdings in TransMedics Group were worth $782,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of TMDX. Braidwell LP bought a new position in shares of TransMedics Group in the 4th quarter valued at about $57,493,000. Norges Bank bought a new position in shares of TransMedics Group in the 4th quarter valued at about $22,861,000. Mackenzie Financial Corp grew its position in shares of TransMedics Group by 73.0% in the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock valued at $51,635,000 after acquiring an additional 349,403 shares during the period. Dimensional Fund Advisors LP grew its position in shares of TransMedics Group by 1,565.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company’s stock valued at $16,820,000 after acquiring an additional 253,624 shares during the period. Finally, Emerald Advisers LLC grew its position in shares of TransMedics Group by 146.3% in the 4th quarter. Emerald Advisers LLC now owns 371,711 shares of the company’s stock valued at $23,176,000 after acquiring an additional 220,804 shares during the period. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the transaction, the director now directly owns 2,866 shares in the company, valued at $362,405.70. This represents a 63.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the sale, the insider now directly owns 13,955 shares in the company, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,418 shares of company stock worth $1,512,613 in the last three months. 7.00% of the stock is owned by corporate insiders.

TransMedics Group Price Performance

Shares of TransMedics Group stock opened at $142.88 on Friday. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a 50-day simple moving average of $108.75 and a two-hundred day simple moving average of $82.45. The stock has a market capitalization of $4.83 billion, a price-to-earnings ratio of 152.00 and a beta of 2.10.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to analysts’ expectations of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business’s revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.35 EPS. Analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TMDX. Canaccord Genuity Group reissued a “buy” rating and issued a $104.00 price objective on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler restated an “overweight” rating and set a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer raised their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Finally, Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Tuesday, June 3rd. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.11.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.